EMA Authorised: Vyndaqel (tafamidis) — Pfizer Europe MA EEIG

View source ↗

Summary

The European Medicines Agency authorised Vyndaqel (tafamidis) for amyloidosis, with Pfizer Europe MA EEIG as the marketing authorisation holder, and the designa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• Vyndaqel (tafamidis)

Snippet

Status: Authorised. Therapeutic area: Amyloidosis. MAH: Pfizer Europe MA EEIG. Decision date: 12/03/2026. Orphan medicine